Axiom Biosciences Plans Landmark Hong Kong IPO, Becoming First U.S. Biotech to List on HKEX
核心洞察
Axiom Biosciences (搜索) announced its intention to pursue an initial public offering on the Main Board of the Hong Kong Stock Exchange, aiming to become the first U.S. biotechnology company to achieve a primary listing in Hong Kong.
The company's lead regenerative therapy, developed with South Korea-based Medinno Inc. (搜索), has produced positive early results in newborns with severe intraventricular hemorrhage (搜索) and hypoxic-ischemic encephalopathy (搜索).
Axiom's platform has received two U.S. FDA Rare Pediatric Disease Designations and has been supported by eight competitive research grants from U.S. federal agencies and the State of California.
Axiom Biosciences (搜索), a clinical-stage biotechnology company headquartered in San Diego, California, announced on July 21, 2026 its intention to pursue an initial public offering on the Main Board of The Stock Exchange of Hong Kong (HKEX (搜索)). The proposed listing would position Axiom as the first U.S. biotechnology company to pursue a primary listing in Hong Kong, marking a significant departure from the traditional path of listing on Nasdaq or the New York Stock Exchange.
"Some of the most important science in the world is being built in the United States, but the way it gets funded hasn't kept pace," said Dr. Remo Moomiaie-Qajar, Founder and Chief Executive Officer of Axiom Biosciences (搜索). "We intend to be the first U.S. biotech to list in Hong Kong because that is where deep biotechnology capital and many of our own clinical partners increasingly are. This is about building Axiom as a global company from the start and about opening a path that other American innovators can follow."
The company intends to pursue a secondary U.S. listing in time, building its public profile from Asia outward. The timing of the proposed offering, the number of shares to be offered, and the price range have not yet been determined. The IPO is currently expected to take place in 2027, subject to regulatory review by the HKEX (搜索) and the Securities and Futures Commission, prevailing market conditions, and other customary factors.
Clinical Progress in Neonatal Brain Injury
Axiom's lead regenerative therapy, developed in partnership with South Korea-based Medinno Inc. (搜索), is being studied in newborns with severe intraventricular hemorrhage (搜索) and hypoxic-ischemic encephalopathy (搜索) — conditions characterized by high mortality and few available treatment options. The therapy has produced positive early results in this vulnerable patient population.
The program has received two U.S. FDA Rare Pediatric Disease Designations, underscoring both the severity of the conditions being addressed and the regulatory recognition of the unmet medical need. The company's underlying platform has been supported by eight competitive research grants from U.S. federal agencies and the State of California, providing external validation of the scientific approach.
Platform Expansion into Adult Ischemic Stroke
Building on its pediatric foundation, Axiom is planning an expansion of its platform with a clinical trial in adult ischemic stroke (搜索), a condition that affects roughly 700,000 Americans each year. This strategic move reflects the company's broader ambition to advance programs from rare pediatric conditions toward larger indications.
Founded in 2018 and formerly known as Cytonus Therapeutics, Axiom Biosciences (搜索) is developing next-generation regenerative therapies and targeted biologics through advanced cellular engineering and translational science. The company's pipeline spans neurology, inflammation, and regenerative medicine.
The announcement reflects what the company describes as a broader shift in where the world's most ambitious science finds the ecosystem to thrive, with Axiom charting a course toward a market with deep biotechnology expertise, a strong appetite for clinical-stage innovation, and direct proximity to Asian partners and capital already advancing its science.